Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

NCT04924101 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: MK-4830
BIOLOGICAL: Boserolimab
DRUG: Lenvatinib
DRUG: Etoposide
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

Merck Sharp & Dohme LLC